Author Correction: SLMO2 is a potential prognostic and immunological biomarker in human pan-cancer

Correction to: Scientifc Reports 10.1038/s41598-024-51720-5, published online 11 January 2024

The original version of this Article contained errors in the Results, Discussion and Figures 6, 8, 9.

In the Results section, the subheading ‘High levels of SLMO2 predicts poor clinical outcomes in TCGA’,

now reads:

“High levels of SLMO2 predicts poor clinical outcomes in several cancer types”

Under the subheading, ‘Mutation feature of SLMO2 in pan-cancer’,

“The results showed that LUCA carried the highest frequency of SLMO2 mutations (17.95%), mainly manifested as “Amplifcation”.”

now reads:

“The results showed that lung cancer carried the highest frequency of SLMO2 mutations (17.95%), mainly manifested as “Amplifcation”.”

“Additionally, high frequencies of SLMO2 mutations were found in OV (17.22%) and UECA (12.5%), predominantly in the “Amplifed” form (Fig. 5A).”

now reads:

“Additionally, high frequencies of SLMO2 mutations were found in OV (17.22%) and UEC (12.5%), predominantly in the “Amplifed” form (Fig. 5A).”

Under the subheading ‘DNA methylation level of SLMO2 in pan-cancer’,

“The results showed that the methylation level of SLMO2 in CESE, COAD, ESCA, HNSC, LUSC, PAAD, READ and UCEC was lower than that in normal tissues (Fig. 6A–H). This may be an explanation for the high expression of SLMO2 in these tumors. In BRCA, KIPC, KIRC and THCA, the methylation level of SLMO2 was higher than that of normal tissues (Fig. 6I–L).”

Figure 6.

DNA Methylation Level of SLMO2 in Pan-Cancer. (A–L) Promoter methylation level of SLMO2 in CESE, COAD, ESCA, HNSC, LUSC, PAAD, READ, UCEC, BRCA, KIPC, KIRC and THCA.

now reads:

“The results showed that the methylation level of SLMO2 in CESC, COAD, ESCA, HNSC, LUSC, PAAD, READ and UCEC was lower than that in normal tissues (Fig. 6A–H). This may be an explanation for the high expression of SLMO2 in these tumors. In BRCA, KIRP, KIRC and THCA, the methylation level of SLMO2 was higher than that of normal tissues (Fig. 6I–L).”

In the Discussion section,

“Using the UALCAN, we observed that SLMO2 promoter methylation levels were significantly lower in CESE, COAD, ESCA, HNSC, LUSC, PAAD, READ and UCEC, while higher in BRCA, KIPC, KIRC and THCA compared to normal tissues.”

now reads:

“Using the UALCAN, we observed that SLMO2 promoter methylation levels were significantly lower in CESC, COAD, ESCA, HNSC, LUSC, PAAD, READ and UCEC, while higher in BRCA, KIRP, KIRC and THCA compared to normal tissues.”

In addition, several labels and tumor abbreviations in Figures 6, 8, 9 were incorrect. The original Figures 6, 8 and 9 and accompanying legends appear below.

Figure 8.

SLMO2 Related Gene Enrichment Analysis. (A) Prediction analysis of SLMO2 interacting proteins. (B) Correlation of SLMO2 with 20 interacting proteins bound by SLMO2 in pan-cancer. (C) Intersection analysis of SLMO2-related genes and SLMO2-interaction partners. (D) Correlations of SLMO2 with DDX27 and NELFCD.

Figure 9.

Effects of SLMO2 on proliferation and migration of MDA-MB-231 and A549 cells in vitro. (A) Western blot was used to detect siRNA-SLMO2 infection in MDA-MB-231 and A549 cells. (B) Proliferation assay was used to evaluate cell proliferation in MDA-MB-231 and A549 cells. (C) Clone formation assay was performed to evaluate the growth of MDA-MB-231 and A549 cells. (D) Transwell assays were performed to assess cell migration in MDA-MB-231 and A549 cells.

The original Article has been corrected.